Goldman Sachs downgraded Apria from Buy to Neutral and set a new price target of $29.00 from $32.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/11/2022 | $37.50 | Buy → Neutral | UBS |
| 1/10/2022 | $39.00 | Buy | Citigroup |
| 11/19/2021 | $39.00 | Buy | Citigroup |
| 11/8/2021 | $43.00 | Buy | Citigroup |
| 7/19/2021 | $32.00 → $29.00 | Buy → Neutral | Goldman Sachs |
| 6/30/2021 | $33.00 | Buy | Citigroup |
INDIANAPOLIS, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Apria, Inc. (the "Company" or "Apria") (NASDAQ:APR), a leading provider of home medical equipment, supplies and related services in the United States, announced today the appointment of Christopher G. Lee as Chief Accounting Officer, a newly created position. Mr. Lee will report to Debra Morris, Apria's Chief Financial Officer. Mr. Lee has 18 years of accounting and financial leadership experience. He joined Apria in February 2009 and has risen internally to his most recent role as Senior Vice President, Accounting and Finance. Prior to joining Apria, Mr. Lee was with Deloitte & Touche. Mr. Lee is a graduate of the University of California a
INDIANAPOLIS, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Apria, Inc. (the "Company" or "Apria") (NASDAQ:APR), a leading provider of integrated home healthcare equipment and related services in the United States, announced today financial results for the fourth quarter and full year ended December 31, 2021. As previously announced, the Company will not be hosting a conference call to discuss its financial results. "We reported solid fourth quarter financial results and 2021 was a good year for Apria. Our team did an excellent job operating and executing at a high level while navigating the challenges from the COVID-19 pandemic, as well as a major product recall and supply chain constraints. Fourth
INDIANAPOLIS, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Apria, Inc. (the "Company" or "Apria") (NASDAQ:APR), a leading provider of home medical equipment, supplies and related services in the United States, announced today that the waiting period has expired under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, in connection with its previously announced transaction with Owens & Minor, Inc. The closing of the transaction remains subject to approval by holders of a majority of the Company's outstanding common stock and other customary closing conditions. About Apria Apria is a leading provider of integrated home healthcare equipment and related services in the United States,
Highly Complementary Transaction Expands Patient Direct Offering Year-One Accretion Across Key Financial Metrics and Free Cash Flow Enhancement Creates a Leading Platform for Future Growth Owens & Minor, Inc. ("Owens & Minor") (NYSE:OMI) and Apria, Inc. ("Apria") (NASDAQ:APR) today announced that the companies have entered into a definitive agreement pursuant to which Owens & Minor will acquire Apria for $37.50 in cash per share of common stock, representing an equity value of approximately $1.45 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220110005291/en/ "I'm very excited about the acquisition of Apria, which wil
4 - Apria, Inc. (0001735803) (Issuer)
4 - Apria, Inc. (0001735803) (Issuer)
4 - Apria, Inc. (0001735803) (Issuer)
SC 13G/A - Apria, Inc. (0001735803) (Subject)
SC 13G - Apria, Inc. (0001735803) (Subject)
SC 13G - Apria, Inc. (0001735803) (Subject)
15-12B - Apria, Inc. (0001735803) (Filer)
25-NSE - Apria, Inc. (0001735803) (Subject)
S-8 POS - Apria, Inc. (0001735803) (Filer)
UBS downgraded Apria from Buy to Neutral and set a new price target of $37.50
Citigroup resumed coverage of Apria with a rating of Buy and set a new price target of $39.00
Citigroup resumed coverage of Apria with a rating of Buy and set a new price target of $39.00
Highly Complementary Transaction Expands Patient Direct Offering Year-One Accretion Across Key Financial Metrics and Free Cash Flow Enhancement Creates a Leading Platform for Future Growth Owens & Minor, Inc. ("Owens & Minor") (NYSE:OMI) and Apria, Inc. ("Apria") (NASDAQ:APR) today announced that the companies have entered into a definitive agreement pursuant to which Owens & Minor will acquire Apria for $37.50 in cash per share of common stock, representing an equity value of approximately $1.45 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220110005291/en/ "I'm very excited about the acquisition of Apria, which wil
INDIANAPOLIS, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Apria, Inc. (the "Company" or "Apria") (NASDAQ:APR) announced today that it will release fiscal third quarter 2021 financial results on Thursday, November 4, 2021 after the market closes. In conjunction, the company will host a conference call to review results at 5:00 p.m. (ET) on the same day. Conference Call Details The conference call can be accessed by dialing (833) 362-0207 for U.S. participants, or (914) 987-7676 for international participants, referencing conference ID 4161279; or via a live audio webcast that will be available online at https://ir.apria.com/. A replay of the call will be available via webcast for on-demand listeni
INDIANAPOLIS, July 22, 2021 (GLOBE NEWSWIRE) -- Apria, Inc. (the "Company" or "Apria") (NASDAQ:APR) announced today that it will release fiscal second quarter 2021 financial results on Thursday, August 5, 2021 after the market closes. In conjunction, the company will host a conference call to review results at 5:00 p.m. (ET) on the same day. Conference Call Details The conference call can be accessed by dialing (833) 362-0207 for U.S. participants, or (914) 987-7676 for international participants, referencing conference ID # 5380517; or via a live audio webcast that will be available online at https://ir.apria.com/. A replay of the call will be available via webcast for on-demand listen
Although oil futures traded higher on Wednesday, there were a few notable insider trades. When insiders sell shares, it indicates their concern in the company’s prospects or that they view the stock as being overpriced. Either way, this signals an opportunity to go short on the stock. Insider sales should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a selling decision. Below is a look at a few recent notable insider sales. For more, check out Benzinga's insider transactions platform. Inspire Medical Systems The Trade: Inspire Medical Systems, Inc. (NYSE:INSP) CEO and President Timothy P Herbert sold a total o
Merger activity remained steady with five new deals announced, four deals completed and one deal terminated. Two of the five new deals announced were potential deals in the works. TEGNA Inc. (NYSE:TGNA) Founded in 1906 and headquartered in Tysons, Virginia, TEGNA is a digital media and marketing services company. It was created on June 29, 2015, when the Gannett Company split into two publicly traded companies. We first added TEGNA as a potential deal in the works on August 16, 2019, when Apollo Global Management (NYSE:APO) approached the company about a deal. TEGNA’s price after this announcement was $14.28. On January 21, 2020, another large investor in Tegna (NYSE:TGNA) wanted the c
Apria (NASDAQ:APR) reported its Q4 earnings results on Monday, February 28, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Apria missed estimated earnings by 2.22%, reporting an EPS of $0.44 versus an estimate of $0.45. Revenue was up $2.74 million from the same period last year. Past Earnings Performance Last quarter the company beat on EPS by $0.13 which was followed by a 2.35% drop in the share price the next day. Here's a look at Apria's past performance: Quarter Q3 2021 Q2 2021 Q1 2021 Q4 2020 EPS Estimate 0.47 0.38 0.25 0.23 EPS Actual 0.60 0.54 0.08 26.06 Re